100 Saw Mill Road
United States - Map
Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. Its lead product candidate is a glucagon emergency management (GEM) device that is intended to treat diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. The company is conducting a Phase 1 clinical trial to assess the pharmacokinetic and pharmacodynamic profiles of BIOD-961, the reconstituted glucagon formulation intended for use in the GEM device. It also develops ultra-rapid-acting proprietary insulin formulations, such as BIOD-123, which has been evaluated in a Phase 2 clinical trial combining recombinant human insulin with its proprietary combination of excipients; and BIOD-531, a concentrated ultra-rapid-acting insulin formulation. The company was founded in 2003 and is headquartered in Danbury, Connecticut.
|Dr. Errol B. De Souza Ph.D.,
Chief Exec. Officer, Pres and Director
|Mr. Paul S. Bavier ,
Chief Admin. Officer, VP of Corp. Devel., Gen. Counsel and Sec.
|Dr. Alan Krasner M.D.,
Chief Medical Officer
|Mr. Gary G. Gemignani ,
Chief Financial Officer and Principal Accounting Officer
|Mr. Robert Feldstein ,
VP of Patent & Intellectual Property
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|